Skip to content

IBD and Cannabinoid Medicine

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A with one of their gastroenterologists on the subject. 

People suffering from IBD often have symptoms that can easily interfere with life’s daily activities.  Those symptoms include:

  • Abdominal cramps and pain
  • Diarrhea that may be bloody
  • Severe urgency to have a bowel movement
  • Fever
  • Weight loss
  • Loss of appetite
  • Iron deficiency anemia due to blood loss

With many states that allow medical marijuana including IBD in their ‘qualifying conditions’ list, patients have been able to use cannabinoid medicine in conjunction with their traditional treatment to find symptom relief.  Our data at Arfinn Med indicates that patients adding cannabinoid treatment to their regiment have seen an improvement in their symptoms, indicating a 3.9 out of 5.0 on our symptom relief scale.

A screenshot of a cell phone

Description automatically generated

If you are suffering from IBD and are interested in learning more about cannabinoid medicine, please reach out to your physician to discuss ways of incorporating it into your existing treatment. If your physician would like more information, please refer them to Arfinn Med and its EMR and data portal focusing on complimentary and alternative medicines (CAM).

Resources:

https://healthblog.uofmhealth.org/digestive-health/cannabis-for-treating-ibd-hope-or-hype

https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-syndrome#1

https://www.healthline.com/health/crohns-disease/facts-statistics-infographic#1

Stories you may be interested in

Finally, Georgia can grow medical marijuana. Here’s what you need to know.

Four years ago, Governor Nathan Deal signed into law Haleigh’s Hope Act, which made low-THC cannabis oil legal to use by those with certain medical conditions. However, as it was still against the law to buy or grow marijuana in the state, it was virtually impossible to obtain the oil in Georgia. Patients were forced…
Read More

$2.7 million awarded for medical marijuana research in Colorado

The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More

An Alternative Treatment for Parkinson’s Patients

April is Parkinson’s Awareness Month and an opportune time to highlight the disease and how medical marijuana may be a beneficial treatment option for those living with the condition. Many Parkinson’s patients find themselves desperate for alternative treatment options that provide sufficient relief of their symptoms and help avoid or postpone the need for surgery…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

After marijuana edibles helped dying Holocaust survivor battle Alzheimer’s, his family’s foundation pushes for more research

A Massachusetts family’s experience giving marijuana edibles to their dying patriarch is set to kick off a desperately needed investigation into how cannabis might treat some of the more troubling symptoms of Alzheimer’s disease, a condition that affects 5.7 million Americans. Read the full story here.
Read More

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More

Leave a Comment

You must be logged in to post a comment.